NEW YORK, Aug. 29, 2016 /PRNewswire/ -- The generic injectable drug segment is a rapidly evolving and highly competitive
market that lacks a true data compass to assist decision makers in mapping strategies for success in this segment. Attempting to determine the optimal time to file an ANDA application is a process that can be worth significant profits for first-to-filers.
But it is a process that is marked by little in the way of analytical decision support and in which litigation has become a staple defensive mechanism for both the filer and the branded drug owner. There are 235 distinct APIs for which there is at least one approved generic injectable ANDA. These 235 APIs account for 1,167 approved ANDAs. Including all approved doses, the current universe of generic injectables consists of 1,699 unique injectable products. These products are currently marketed and supplied by slightly less than one hundred companies. Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.Generic Injectables What You Will Learn
- Provides detailed analysis of generic drugs supplied as injectables and assesses key market segments, market dynamics and potential product opportunities- Presents the competitive picture for generic injectables in two dozen drug classes- Evaluates the importance of ANDA filing strategies and indirect ANDA acquisition on participant growth prospects- Analyzes the impact of patents, exclusivity and litigation on participant market sector prospects- Assesses the market presence and product position of the top twenty-four generic injectables suppliers- Evaluates the impact of economic, technology, and regulatory factorsRead the full report: http://www.reportlinker.com/p03858945-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com
__________________________Contact Clare: [email protected] US: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/generic-injectables-300319668.html